Skip to main content
. 2017 Nov 20;8(63):106527–106537. doi: 10.18632/oncotarget.22507

Figure 5. miR-29b antagonism impairs in vitro anti-MM activity of EZH2 inhibitors.

Figure 5

(A) QRT-PCR analysis of miR-29b expression levels in AMO-BZB transduced with GFP control or miR-29b inhibitors (antimiR-29b). Trypan blue exclusion assay (B) and CTG viability assay (C) were performed in AMO-BZB cells stably transduced with GFP control or miR-29b inhibitors (anti-miR-29b), 72 hours after treatment with 2 μM DZnep, 5 μM GSK343 or 5 μM EPZ005687. *P < 0.05.